Literature DB >> 3871330

Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.

D D Gerbracht, V D Steen, G L Ziegler, T A Medsger, G P Rodnan.   

Abstract

Eighty-seven patients diagnosed as having primary Raynaud's phenomenon (Raynaud's disease) were reexamined after this symptom had been present for a mean of 8.8 years (range 2.0-34.5). One or more additional clinical feature(s) suggesting an underlying connective tissue disease were found in 12 patients (14%) at first evaluation, and in 23 (26%) by the last evaluation. The most frequent findings were puffy fingers (10 patients), digital tip pitting scars (8 patients), and digital tip ulcerations (6 patients). Distal esophageal hypomotility and/or decreased pulmonary diffusing capacity for carbon monoxide were found in 12 patients. Only 4 individuals (5%) developed clear evidence of a connective tissue disease, and in all cases, the diagnosis was the CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) syndrome variant of systemic sclerosis. This condition became obvious 8-17 years after the onset of Raynaud's phenomenon. One or more serologic test values were initially abnormal in 2 of these CREST syndrome patients, as well as in 12 patients who continued to have primary Raynaud's phenomenon at the last evaluation. The combination of puffy fingers, digital pitting scars, and serum anticentromere antibody, all consistent with CREST syndrome, occurred in a small group of patients. None of the 78 patients whose serologic tests were repeated during followup had a change in the serologic profile. These results suggest that only a small proportion of patients with primary Raynaud's phenomenon develop one of the connective tissue diseases during the first decade after onset. When such a disorder does appear, systemic sclerosis with the CREST syndrome variant is the most likely eventual diagnosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871330     DOI: 10.1002/art.1780280114

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].

Authors:  M J Behne; U Hauswirth; A Menz; N Brüllke; U Müllerleile; I Moll
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

Review 3.  Connective tissue disease in patients presenting with Raynaud's phenomenon alone.

Authors:  C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

4.  Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD.

Authors:  M G Danieli; P Fraticelli; A Salvi; A Gabrielli; G Danieli
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

5.  Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon.

Authors:  J S Coppock; J M Hardman; P A Bacon; K L Woods; M J Kendall
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

6.  Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon.

Authors:  M Cruz; G Mejia; C Lavalle; J J Cortes; P A Reyes
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

7.  Prevalence of symptoms of Raynaud's phenomenon in general practice.

Authors:  A Silman; S Holligan; P Brennan; P Maddison
Journal:  BMJ       Date:  1990-09-22

8.  Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon.

Authors:  Fernanda Falcini; Donato Rigante; Marcello Candelli; Giorgia Martini; Fabrizia Corona; Antonella Petaccia; Francesco La Torre; Carmela G L Raffaele; Marco Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2014-11-28       Impact factor: 2.980

9.  Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.

Authors:  C G Kallenberg; A A Wouda; M H Hoet; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

10.  Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjögren's syndrome: a retrospective analysis.

Authors:  Veli Yazisiz; Ali Berkant Avci; Funda Erbasan; Evren Kiriş; Ender Terzioğlu
Journal:  Rheumatol Int       Date:  2008-09-18       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.